Thats where GLP-1 Support comes in
Ozempic (semaglutide) highlights of prescribing information, Food and Drug Administration (2025) FDA approves Ozempic (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk USA (2025) Alcohol-associated liver disease, Johns Hopkins Medicine (2025) Nonalcoholic fatty liver disease (NAFLD) & NASH, National Institute of Diabetes and Digestive and Kidney Diseases (2021) Symptoms & causes of NAFLD & NASH, National Institute of Diabetes and Digestive and Kidney Diseases (2021) Efficacy and safety of semaglutide in non-alcoholic fatty liver disease, World Journal of Gastroenterology (2023) Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis, Diabetes & Metabolic Syndrome: Clinical Research & Reviews (2023) GLP-1 receptor agonists in non-alcoholic fatty liver disease: Current evidence and future perspectives, International Journal of Molecular Sciences (2023) AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease, Hepatology (2023) Rezdiffra (resmetirom) highlights of prescribing information, Food and Drug Administration (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
GLP-1 medications are a class of drugs developed initially to help manage type 2 diabetes, lower blood sugar levels, and are currently promoted for weight loss
Lamberts L-Carnitine is in a form that is ready to be absorbed by the body without needing to be broken down by digestive enzymes
Nasseri and our dedicated team at Noor Medical Spa are committed to providing personalized consultation and continuous monitoring for sustainable weight loss
